γ-Melanocyte-stimulating hormone
Names | |
---|---|
IUPAC name
L-Tyrosyl-L-valyl-L-methionylglycyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-L-α-aspartyl-L-arginyl-L-phenylalaninamide
| |
Other names
gamma-MSH, γ-melanotropin, γ-melanocortin, γ-intermedin
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
Properties | |
C74H99N21O16S | |
Molar mass | 1570.80 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
γ-Melanocyte-stimulating hormone (γ-MSH) is an endogenous peptide hormone and neuropeptide.[1] It is a melanocortin, specifically, one of the three types of melanocyte-stimulating hormone (MSH), and is produced from proopiomelanocortin (POMC).[1] It is an agonist of the MC1, MC3, MC4, and MC5 receptors.[1] It exists in three forms, γ1-MSH, γ2-MSH, and γ3-MSH.[2]
γ-MSH regulated cardiovascular functions. γ-MSH effects are measured through the effects it has on the central neural pathway dispersed throughout the kidney.[3] It is not moderated based on tubular sodium transport. Gamma-MSH activates MC3R in renal tubular cells by limiting sodium absorption by inhibiting the central neural pathway.[3] This regulates sodium balance and blood pressure. If MC3R is absent then there is resistance in γ-MSH which results in hypertension on HSD.[4]
See also
[edit]References
[edit]- ^ Jump up to: a b c Kastin A (26 January 2013). Handbook of Biologically Active Peptides. Academic Press. pp. 838–844. ISBN 978-0-12-385096-6.
- ^ Jakubke HD, Sewald N (8 September 2008). Peptides from A to Z: A Concise Encyclopedia. John Wiley & Sons. pp. 216–. ISBN 978-3-527-62117-0.
- ^ Jump up to: a b Kathpalia PP, Charlton C, Rajagopal M, Pao AC (May 2011). "The natriuretic mechanism of Gamma-Melanocyte-Stimulating Hormone". Peptides. 32 (5): 1068–1072. doi:10.1016/j.peptides.2011.02.006. PMC 3112371. PMID 21335042.
- ^ Reudelhuber TL (April 2003). "Salt-sensitive hypertension: if only it were as simple as rocket science". The Journal of Clinical Investigation. 111 (8): 1115–1116. doi:10.1172/jci200316993. PMC 152948. PMID 12697727.